Heart failure remains a significant public health concern globally, impacting millions and contributing to increased morbidity and mortality rates. Among patients suffering from heart failure, those with chronic kidney disease (CKD) represent a vulnerable subgroup, often facing compounded health risks. The introduction of finerenone (Kerendia), a non-steroidal selective mineralocorticoid receptor antagonist, aimed to provide therapeutic benefits specifically for this population. However, recent findings from the FINEARTS-HF trial indicate that the anticipated renal benefits associated with finerenone might not be as pronounced as expected, particularly in patients with mildly reduced or preserved ejection fraction.
A secondary analysis of the FINEARTS-HF trial unveiled some surprising results regarding finerenone’s impact on renal function. The study found that although finerenone was designed to support kidney health, it yielded a higher incidence of adverse kidney events compared to placebo. Specifically, the composite outcome of a sustained 50% decline in estimated glomerular filtration rate (eGFR) or kidney failure occurred in 75 events within the finerenone group compared to 55 events within the placebo group, signifying a hazard ratio of 1.33. This finding raises critical questions about the drug’s effectiveness and its potential implications for clinical practice.
Beyond the initial outcomes, a deeper evaluation revealed that even in more severe scenarios—such as a decline of 57% in eGFR—the trend remained similar. The test results place finerenone under scrutiny, casting doubt on its role as a reliable option for kidney protection among patients categorized as “low risk” for adverse kidney events.
Addressing the nuances of the FINEARTS-HF trial, it is essential to discuss the patient population included in the study. Participants were older adults with an average age of around 69 years, many of whom had previously experienced hospitalizations due to heart failure. The majority were treated with beta-blockers and loop diuretics, highlighting a population already engaged with complex treatment regimens.
The presence of CKD among these patients was notable, as nearly half were affected by varying degrees of kidney impairment. The correlation between CKD and heart failure is particularly alarming; this intersection leads to elevated risk profiles that extend beyond standard heart failure considerations. Nevertheless, the results showcased by Finnian R. McCausland from Brigham and Women’s Hospital emphasized that while finerenone does not impact kidney outcomes significantly, it does show promise in managing markers of kidney function, such as microalbuminuria and macroalbuminuria.
Despite the lack of substantial gains in the primary kidney outcomes, the fact that finerenone showed beneficial effects on reducing microalbuminuria indicates potential for long-term renal protection. The argument made by Ian de Boer, MD, suggests that diminishing albumin levels could lead to beneficial changes in eGFR over a more extended period, though substantial improvements remain unlikely given the population’s baseline risk indicators.
It is essential to recognize the chronic nature of CKD, which progresses gradually over years or decades. The short-term follow-up in this study raises concerns over our ability to ascertain definitive long-term outcomes for finerenone within this population. Notably, the primary analysis earlier this year at the European Society of Cardiology meeting demonstrated that finerenone did positively reduce urgent cardiovascular events and heart failure-related deaths.
The findings derived from the FINEARTS-HF trial indicate an intricate landscape surrounding the use of finerenone in heart failure patients with CKD. While the medication exhibits potential in some areas—particularly regarding microalbuminuria—its overall efficacy concerning renal outcomes remains questionable.
Going forward, both the research community and clinicians must exercise caution and consider the complexities of deploying finerenone within a patient demographic already burdened by elevated risks. Addressing these concerns requires more comprehensive data over extended periods to determine whether finerenone can live up to its potential as a transformative treatment option for heart failure patients with coexisting renal conditions. As the landscape of research continues to evolve, adapting therapeutic approaches to address these challenges will be paramount for improving patient outcomes in this vulnerable population.
Leave a Reply